Literature DB >> 12047986

WHO: the casualties and compromises of renewal.

Richard Horton1.   

Abstract

The World Health Organization is the leading international agency in health. WHO's reputation reached a peak in the 1970s with the then director-general Halfdan Mahler's advocacy of Health for All by the Year 2000 and the successful worldwide eradication of smallpox. The 1980s and 1990s saw WHO lose much of its authority. Too easily, the blame was put on one man-Mahler's successor, Hiroshi Nakajima. In 1998, Gro Harlem Brundtland, Figure 1 a former Prime Minister of Norway, took office and WHO began a period of major strategic and structural reform. Almost 4 years into her first term as director-general, I visited WHO's headquarters in Geneva to learn about Dr Brundtland's successes and failures. Figure 2 The ground rules of my visit were that I could talk with anybody and attend almost any meeting (budget discussions were excluded). I interviewed Dr Brundtland, executive directors, members of the staff association, and directors and project managers of programmes such as StopTB, Roll Back Malaria, HIV-AIDS, violence prevention, polio eradication, essential drugs and medicines, and sustainable development. At senior levels, WHO is confident and clear about its purpose-in a way that matches Mahler's vision and goes beyond it in results. Brundtland told me that her most important achievements were to have "strengthened the credibility of WHO" and to have "raised the awareness of health on to the political and global development agendas". But there is a troubling schism between the aspirations of its leadership and the realities faced by the organisation on the ground. Rapid change during the past 4 years has reinvigorated WHO's mandate, but poor management has created new tensions that the organisation's leadership seems unwilling to address.

Entities:  

Mesh:

Year:  2002        PMID: 12047986     DOI: 10.1016/S0140-6736(02)08523-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

Review 1.  Guidelines 2.0: do no net harm-the future of practice guideline development in asthma and other diseases.

Authors:  Holger J Schünemann
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

2.  Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders.

Authors:  Corrado Barbui; Tarun Dua; Mark van Ommeren; M Taghi Yasamy; Alexandra Fleischmann; Nicolas Clark; Graham Thornicroft; Suzanne Hill; Shekhar Saxena
Journal:  PLoS Med       Date:  2010-08-31       Impact factor: 11.069

3.  Developing clinical practice guidelines: target audiences, identifying topics for guidelines, guideline group composition and functioning and conflicts of interest.

Authors:  Martin P Eccles; Jeremy M Grimshaw; Paul Shekelle; Holger J Schünemann; Steven Woolf
Journal:  Implement Sci       Date:  2012-07-04       Impact factor: 7.327

4.  Improving the use of research evidence in guideline development: introduction.

Authors:  Andrew D Oxman; Atle Fretheim; Holger J Schünemann
Journal:  Health Res Policy Syst       Date:  2006-11-20

5.  Evidence-informed health policy 1 - synthesis of findings from a multi-method study of organizations that support the use of research evidence.

Authors:  John N Lavis; Andrew D Oxman; Ray Moynihan; Elizabeth J Paulsen
Journal:  Implement Sci       Date:  2008-12-17       Impact factor: 7.327

6.  Transparent development of the WHO rapid advice guidelines.

Authors:  Holger J Schünemann; Suzanne R Hill; Meetali Kakad; Gunn E Vist; Richard Bellamy; Lauren Stockman; Torbjørn Fosen Wisløff; Chris Del Mar; Frederick Hayden; Timothy M Uyeki; Jeremy Farrar; Yazdan Yazdanpanah; Howard Zucker; John Beigel; Tawee Chotpitayasunondh; Tran Tinh Hien; Bülent Ozbay; Norio Sugaya; Andrew D Oxman
Journal:  PLoS Med       Date:  2007-05       Impact factor: 11.069

7.  Proposing a sequential comparative analysis for assessing multilateral health agency transformation and sustainable capacity: exploring the advantages of institutional theory.

Authors:  Eduardo J Gómez
Journal:  Global Health       Date:  2014-05-20       Impact factor: 4.185

Review 8.  SARS: political pathology of the first post-Westphalian pathogen.

Authors:  David P Fidler
Journal:  J Law Med Ethics       Date:  2003       Impact factor: 1.718

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.